PVLA
HOLD / NEUTRALMeanRevComposite
36.40
Technical
83.40
Fundamental
20.80
Rank
—
Price
143.94
Hurst
0.00
As of
Jul 22, 2026
Daily
Palvella Therapeutics, Inc.
HealthcareBiotechnologyPalvella Therapeutics is a clinical-stage biotech company developing topical treatments for rare genetic skin conditions. Its main candidate is QTORIN rapamycin, a gel formulation currently being tested in Phase 3 trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations, with additional development for angiokeratomas and related skin disorders. The company also has a separate candidate, QTORIN pitavastatin, in development for disseminated superficial actinic porokeratosis.
Market cap
$2.1B
P/E (trailing)
—
P/E (forward)
-18.49
PEG ratio
—
Dividend yield
0.00%
Beta
—
52w range
71.55 – 161.38
Return on equity
-46.63%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 146.15 (+83.0%) · range 75.06–158.13
Cycle position
53/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 22 · NOT READY · exit proximity 0
Conviction
19/ 100 · maturity 0%
Buildup.3313
EMA entry setup.4222
Fundamentals.2521
Volume profile
POC
152.17
Price vs POC
-4.0%
Overhead supply
35%
Runway
+0.8%
Value area 123.32–157.70 · 35% of 120d volume overhead · moderate overhead
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +5.47% | +10.96% | mature |
| 40d | +8.54% | +10.96% | mature |